Skip to main content

Anna Penalba Morenilla

Institutions of which they are part

Main researcher
Neurovascular Diseases
Vall Hebron Institut de Recerca

Anna Penalba Morenilla

Institutions of which they are part

Main researcher
Neurovascular Diseases
Vall Hebron Institut de Recerca

Projects

PROOF: Penumbral Rescue by Normobaric O=O Administration in Patients With Ischaemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial

IP: Joan Montaner Villalonga
Collaborators: Estela Sanjuan Menendez, Anna Penalba Morenilla, Tamara Del Rio Higueras, Ariadna Martín Balcells, Olalla Pancorbo Rosal, Olga Sánchez- Maroto Carrizo, Amaia Latasa Arrazubi, Marcel Lamana Vallverdu, Paula Garcia Rodriguez
Funding agency: EUROPEAN COMMISSION
Funding: 715274.5
Reference: PROOF_H2020PHC2016/MONTANER
Duration: 01/01/2017 - 30/06/2023

RESSTORE: REgenerative Stem cell therapy for STroke in Europe GA No 681044

IP: Joan Montaner Villalonga
Collaborators: Anna Penalba Morenilla
Funding agency: EUROPEAN COMMISSION
Funding: 350000
Reference: RESSTORE_H2020-PHC2015
Duration: 01/09/2015 - 08/11/2018

STROKE BIO-TARGETS: Nuevas estrategias para descubrir biomarcadores de isquemia cerebral y su aplicación como dianas terapéuticas en el ictus

IP: Joan Montaner Villalonga
Collaborators: Anna Penalba Morenilla
Funding agency: Instituto de Salud Carlos III
Funding: 272552.5
Reference: PI15/00354
Duration: 01/01/2016 - 31/12/2018

"Dispositivo Point of Care de Diagnóstico del Ictus mediante Biomarcadores Plasmáticos: 2-Stroke-Chip".

IP: Joan Montaner Villalonga
Collaborators: "Dispositivo Point of Care de Diagnóstico del Ictus mediante Biomarcadores Plasmáticos: 2-Stroke-Chip"., Eva Baldrich Rubio, Anna Penalba Morenilla
Funding agency: Instituto de Salud Carlos III
Funding: 155650
Reference: DTS14/00004
Duration: 01/01/2015 - 31/12/2016

Related news

The TOUCH MSCA-COFUND doctoral training programme, led by UAB and focusing on the field of mental health, has opened its first call for applications, offering 13 doctoral positions.

The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.

La recerca és fonamental per contrarestar els efectes de la pol·lució, que segons l’AEMPS, va ser la causa de més de 300.000 morts prematures a la UE el 2020.

Related professionals

Carlos Molina Cateriano

Carlos Molina Cateriano

Head of group
Stroke research
Read more
Arnau Peñalver Piñol

Arnau Peñalver Piñol

Predoctoral researcher
Epidemiology and Public Health
Read more
Toni Soriano Colomé

Toni Soriano Colomé

Research technician
Cardiovascular Diseases
Read more
Pablo Gabriel Medina

Pablo Gabriel Medina

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.